This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takayama, K.-i. Articles by Inoue, S. Search for Related Content PubMed PubMed Citation Articles by Takayama, K.-i. Articles by Inoue, S.

Amyloid Precursor Protein Is a Primary Androgen Target Gene That Promotes Prostate Cancer Growth

Departments of ¹ Geriatric Medicine and ² Anti-Aging Medicine, Graduate School of Medicine, University of Tokyo; ³ Department of Urology, University of Tokyo Hospital, Bunkyo-ku; ⁴ Research Center for Genomic Medicine, Saitama Medical University, Hidaka; ⁵ Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Meguro-ku; ⁶ Department of Pathology, Tohoku University School of Medicine, Sendai; ⁷ Genomic Sciences Center, Yokohama Institute, RIKEN; ⁸ Division for Gene Research, Center for Biological Resources and Informatics, Tokyo Institute of Technology, Yokohama; and ⁹ CREST, Japan Science and Technology Agency, Kawaguchi, Japan

Requests for reprints: Satoshi Inoue, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-5800-9125; Fax: 81-3-5800-9126; E-mail: INOUE-GER{at}h.u-tokyo.ac.jp.

Key Words: androgen receptor • prostate cancer • amyloid precursor protein • chromatin immunoprecipitation

Androgen receptor (AR) is a critical transcription factor that regulates various target genes and contributes to the pathophysiology of prostate cancer hormone dependently. Here, we identify amyloid precursor protein (APP) as a primary androgen target through chromatin immunoprecipitation (ChIP) combined with genome tiling array analysis (ChIP-chip). ChIP-treated DNA were obtained from prostate cancer LNCaP cells with R1881 or vehicle treatment using AR or acetylated histone H3 antibodies. Ligand-dependent AR binding was further enriched by PCR subtraction. Using chromosome 21/22 arrays, we identified APP as one of the androgen-regulated genes with adjacent functional AR binding sites. APP expression is androgen-inducible in LNCaP cells and APP immunoreactivity was correlated with poor prognosis in patients with prostate cancer. Gain-of-function and loss-of-function studies revealed that APP promotes the tumor growth of prostate cancer. The present study reveals a novel APP-mediated pathway responsible for the androgen-dependent growth of prostate cancer. Our findings will indicate that APP could be a potential molecular target for the diagnosis and treatment of prostate cancer. [Cancer Res 2009;69(1):137–42]

This article has been cited by other articles:

				W. Zhang, J. Zhu, C. L. Efferson, C. Ware, J. Tammam, M. Angagaw, J. Laskey, K. A. Bettano, S. Kasibhatla, J. F. Reilly, et al. Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer Cancer Res., September 15, 2009; 69(18): 7466 - 7472. [Abstract] [Full Text] [PDF]